NEPHROPLUS2026-04-012026-06-30NEPHROPLUS2026-06-30NEPHROPLUS2026-04-012026-06-30in-capmkt:OtherExpenses1MemberNEPHROPLUS2026-04-012026-06-30in-capmkt:OtherExpenses2MemberNEPHROPLUS2026-04-012026-06-30in-capmkt:OtherExpenses3MemberNEPHROPLUS2026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1NEPHROPLUS2026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss2NEPHROPLUS2026-06-30Statement1NEPHROPLUS2026-04-012026-06-30Statement1NEPHROPLUS2026-06-30StatementDynamic1I1Statement1NEPHROPLUS2026-06-30StatementDynamic1I2Statement1NEPHROPLUS2026-06-30StatementDynamic1I3Statement1NEPHROPLUS2026-06-30StatementDynamic1I4Statement1iso4217:INRxbrli:pureiso4217:INRxbrli:shares544647NEPHROPLUSNOTLISTEDINE428V01029Nephrocare Health Services LimitedMain BoardEquity2026-04-012027-03-312026-08-112026-07-24INRMillionsQuarterlyFirst quarterSingle segmentHealthcare2026-08-1115:45:002026-08-1117:10:00Not applicabletrue1falseNo Default as on date.2026-04-012026-06-30UnauditedStandalone17037800006124000017650200004217600000030802000048500001308800007325800001598090000166930000016693000060710000-19410000413000000125630000000012563000013000012576000020068000021.251.22001.251.221. The above standalone financial results of Nephrocare Health Services Limited (formerly Nephrocare Health Services Private Limited) ("the Company") for the quarter ended 30 June 2026, have been prepared in accordance with the Indian Accounting Standard (referred to as 'Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules, 2015, as amended from time to time and in terms of Regulation 33 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. <br /> 2. These standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 11 August 2026. The Statutory auditors of the Company have conducted a 'Limited Review' of the standalone financial results and have issued an unmodified review conclusion thereon. <br /> 3. The standalone figures for the quarter ended 31 March 2026 are the balancing figures between audited standalone figures for the year ended 31 March 2026 and the published unaudited year to date figures for the nine months ended 31 December 2025. <br /> 4. The Company was listed on the stock exchanges on 17 December 2025. Accordingly, the standalone financial results for the corresponding quarter ended 30 June 2025 were not required to be submitted to the stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and were consequently not subjected to audit or limited review by the statutory auditors. The comparative figures for the quarter ended 30 June 2025 as included in these standalone financial results, have been approved by the Board of Directors of the Company at its meeting held on 11 August 2026. <br /> 5. In accordance with Ind AS 108, Operating segments, segment information has been provided in the consolidated financial results of the Company and no separate disclosure on segment information is given in these standalone financial results. <br /> 6. During the year ended 31 March 2026, the Company has completed an initial public offering (IPO) of 18,943,020 equity shares with a face value of INR 2 each at an issue price of INR 460 per share, comprising fresh issue of 7,689,918 shares and an offer for sale of 11,253,102 shares. The Company’s equity shares were listed on the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on 17 December 2025. <br /> The utilisation of net IPO proceeds is summarised below: <br /> Objectives Amount to be utilised as per prospectus Utilisation up to <br /> 30 June 2026 Unutilised as on <br /> 30 June 2026 <br /> Capital expenditure for opening new dialysis clinics in India 1,291.06 127.68 1,163.38 <br /> Pre-payment, or scheduled repayment, in full or part, of certain borrowings availed 1,359.99 1,359.99 - <br /> General corporate purposes 600.48 587.16 13.32 <br /> Total 3,251.53 2,074.83 1,176.70 <br /> 7. During the quarter ended 30 June 2026, the Company received share application money amounting to INR 11.28 million pursuant to the exercise of employee stock options under its ESOP Scheme. Subsequently, on 14 July 2026, the Company allotted 144,320 equity shares against such exercises. <br /> 8. The standalone financial results for the quarter ended 30 June 2026, are available on the BSE Limited website (URL: www.bseindia.com), the National Stock Exchange of India Limited website (URL: nseindia.com) and on the Company's website (URL: https://nephroplus.com/investors).Healthcare professional fees221720000Hospital fees179000000Other expenses331860000Remeasurement gains on defined benefit plans170000Income tax relating to items above-4000013000000130000Public Issues2025-12-1735340500002026-06-30trueCrisil Ratings LimitedfalseKishore KathriCompany Secretary and Compliance OfficerHyderabad2026-08-11Capital expenditure by the Company for opening new dialysis clinics in IndiaNil129106000001276800000Pre-payment, or scheduled repayment, in full or part, of certain borrowings availed by the CompanyNil1359990000013599900000General corporate purposesNil60048000005871600000Issue expensesNil28252000001406400000